证券日报网讯2月13日，中源协和（600645）在互动平台回答投资者提问时表示，公司全资子公司武汉 光谷药业自主研发的VUM02注射液治疗特发性肺纤维化(IPF)处于I期临床试验阶段；公司参股的北京三 有利公司与首都医科大学共同申报的"人牙髓间充质干细胞注射液"治疗慢性牙周炎处于II期临床试验阶 段；公司干细胞临床研究项目已在卫生健康委/NMPA和中央军委后勤保障部完成备案。 ...

Core Viewpoint - Zhongyuan Xiehe announced that its affiliated company, Beijing Sanyouli, in collaboration with Capital Medical University, is progressing with the clinical trials of "human dental pulp mesenchymal stem cell injection" for the treatment of chronic periodontitis, with all participants for Phase II expected to be enrolled by 2024 [1] Group 1 - The company is conducting regular follow-up work for the chronic periodontitis treatment trial [1] - The treatment for idiopathic pulmonary fibrosis has completed all participant dosing in Phase I, and the company is currently organizing clinical safety and efficacy data [1]